Scalper1 News
Drugmaker Bristol-Myers Squibb sold off its diabetes business to partner AstraZeneca on Thursday, shedding a troubled acquisition while advancing its strategy to become a more specialized biopharma company. Its stock hit a 12-year high, closing up 2.3% at 53.82. AstraZeneca (AZN) agreed to pay $2.7 billion upfront for the assets, which include marketed drugs such as Bydureon, Byetta and Onglyza, as well as make $1.4 billion in regulatory and Scalper1 News
Scalper1 News